Research programme: monoclonal antibody therapeutics - IMED

Drug Profile

Research programme: monoclonal antibody therapeutics - IMED

Latest Information Update: 29 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IMED AB
  • Class Monoclonal antibodies
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Graft-versus-host disease; Immunological disorders

Most Recent Events

  • 29 Sep 2009 Preclinical development is ongoing in Sweden
  • 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb
  • 05 Mar 2008 Preclinical trials in Graft-versus-host disease in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top